Fiduciary Trust Co. reduced its holdings in Merck & Co., Inc. (NYSE:MRK) by 3.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 441,070 shares of the company’s stock after selling 14,738 shares during the quarter. Merck & Co., Inc. comprises 1.0% of Fiduciary Trust Co.’s portfolio, making the stock its 22nd biggest holding. Fiduciary Trust Co.’s holdings in Merck & Co., Inc. were worth $33,702,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. WealthPLAN Partners LLC grew its position in Merck & Co., Inc. by 1.6% during the third quarter. WealthPLAN Partners LLC now owns 8,377 shares of the company’s stock worth $626,000 after buying an additional 135 shares in the last quarter. QCI Asset Management Inc. NY boosted its holdings in Merck & Co., Inc. by 4.9% during the fourth quarter. QCI Asset Management Inc. NY now owns 3,178 shares of the company’s stock valued at $243,000 after purchasing an additional 149 shares in the last quarter. Atlas Capital Advisors LLC boosted its holdings in Merck & Co., Inc. by 11.1% during the fourth quarter. Atlas Capital Advisors LLC now owns 1,528 shares of the company’s stock valued at $117,000 after purchasing an additional 153 shares in the last quarter. Traynor Capital Management Inc. boosted its holdings in Merck & Co., Inc. by 1.6% during the fourth quarter. Traynor Capital Management Inc. now owns 9,905 shares of the company’s stock valued at $756,000 after purchasing an additional 156 shares in the last quarter. Finally, Bfsg LLC boosted its holdings in Merck & Co., Inc. by 0.5% during the fourth quarter. Bfsg LLC now owns 33,519 shares of the company’s stock valued at $2,561,000 after purchasing an additional 164 shares in the last quarter. 72.55% of the stock is currently owned by institutional investors.

In other news, Chairman Kenneth C. Frazier sold 20,105 shares of Merck & Co., Inc. stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $82.00, for a total value of $1,648,610.00. Following the completion of the transaction, the chairman now owns 810,859 shares in the company, valued at $66,490,438. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Wendell P. Weeks sold 5,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, February 13th. The shares were sold at an average price of $78.71, for a total transaction of $393,550.00. Following the completion of the transaction, the director now owns 5,100 shares of the company’s stock, valued at approximately $401,421. The disclosure for this sale can be found here. Insiders sold 709,324 shares of company stock valued at $56,162,582 in the last quarter. 0.32% of the stock is currently owned by corporate insiders.

NYSE:MRK opened at $81.49 on Friday. Merck & Co., Inc. has a 1 year low of $52.83 and a 1 year high of $82.12. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.17 and a quick ratio of 0.92. The company has a market capitalization of $219.17 billion, a PE ratio of 18.78, a PEG ratio of 1.99 and a beta of 0.62.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Friday, February 1st. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.01. Merck & Co., Inc. had a net margin of 14.71% and a return on equity of 36.83%. The company had revenue of $11 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the previous year, the company posted $0.98 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 5.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 4.65 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.70%. The ex-dividend date is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 50.69%.

A number of research firms have weighed in on MRK. BMO Capital Markets reaffirmed a “hold” rating on shares of Merck & Co., Inc. in a report on Tuesday, February 19th. Argus lifted their price objective on Merck & Co., Inc. to $95.00 and gave the company a “buy” rating in a report on Wednesday, February 20th. Zacks Investment Research downgraded Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 24th. Citigroup set a $65.00 price objective on Merck & Co., Inc. and gave the company a “hold” rating in a report on Thursday, December 20th. Finally, Credit Suisse Group set a $86.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a report on Thursday, December 13th. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $77.06.

ILLEGAL ACTIVITY WARNING: “Merck & Co., Inc. (MRK) Shares Sold by Fiduciary Trust Co.” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2019/03/15/merck-co-inc-mrk-shares-sold-by-fiduciary-trust-co.html.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Further Reading: What is the price-to-earnings growth (PEG) ratio?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.